Over the past 15 years, significant progress has been made in understanding the role of microorganisms that inhabit our body (also called the microbiome) in shaping human physiological processes. As a result, interest in probiotics has rapidly increased, which are promoted as beneficial bacteria that positively affect various bodily functions. However, despite marketing assurances about the health-promoting properties of probiotics, scientific research shows their low effectiveness in a medical context. There are two key causes that explain the ineffectiveness of probiotics. The first is the selection of the wrong bacterial strains, while the second is the lack of their effective colonization of the digestive system, which is the main area of inhabitation of the microbiome. As part of this research project, we propose new strategies to solve both of these problems. The probability of their success is based on our previous research, published in the journal Nature Immunology in 2021 (Wypych et al.). The first objective is to investigate the prophylactic and therapeutic potential of new bacterial strains in the context of asthma. The second is to develop a method of increasing the effectiveness of bacterial colonization by opsonizing them with the antibody we discovered, supporting the development of specific strains of bacteria. The above approach distinguishes us from existing market solutions, as well as those proposed in the databases of patent documents. First, we propose the use of bacterial strains outside the Lactobacillus and Bifidobacterium families, which dominate the probiotic market. Secondly, we are the first in the world to propose a method to increase the efficiency of bacterial colonization using a monoclonal antibody. These solutions, based on our innovative and original achievements, open the way to the commercialization of products that will be not only unique on the market, but above all more effective.